期刊文献+

Genome-wide characterization of copy number variations in diffuse large B-cell lymphoma with implications in targeted therapy

原文传递
导出
摘要 Diffuse large B-cell lymphoma(DLBCL)is the aggressive form of haematological malignancies with relapse/refractory in∼40%of cases.It mostly develops due to accumulation of various genetic and epigenetic variations that contribute to its aggressiveness.Though large-scale structural alterations have been reported in DLBCL,their functional role in pathogenesis and as potential targets for therapy is not yet well understood.In this study we performed detection and analysis of copy number variations(CNVs)in 11 human DLBCL cell lines(4 activated B-cell–like[ABC]and 7 germinal-centre B-cell–like[GCB]),that serve as model systems for DLBCL cancer cell biology.Significant heterogeneity observed in CNV profiles of these cell lines and poor prognosis associated with ABC subtype indicates the importance of individualized screening for diagnostic and prognostic targets.Functional analysis of key cancer genes exhibiting copy alterations across the cell lines revealed activation/disruption of ten potentially targetable immuno-oncogenic pathways.Genome guided in silico therapy that putatively target these pathways is elucidated.Based on our analysis,five CNV-genes associated with worst survival prognosis are proposed as potential prognostic markers of DLBCL.
出处 《Precision Clinical Medicine》 2019年第4期246-258,共13页 精准临床医学(英文)
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部